Novo Nordisk (NVO) CagriSema Study Misrepresentation Case

• $NVO investors filed a lawsuit against Novo, alleging it misled them about the methodology and outcomes of its REDEFINE-1 obesity trial for the drug CagriSema.

• On December 20, 2024, Novo disclosed that the study achieved only a 22.7% average weight loss, falling its previously 25% target. Following this announcement, $NVO dropped 17.83%.

• $NVO investors can join this case to be notified about potential recovery.

Case Details:

Between November 2, 2022, and December 19, 2024, Novo Nordisk repeatedly assured investors that its REDEFINE-1 trial for CagriSema would achieve at least 25% average weight loss in patients with obesity. The company emphasized the trial’s rigorous design and its confidence in reaching superior results compared to competitors.

However, on December 20, 2024, Novo revealed that the trial followed a "flexible protocol" allowing participants to adjust their dosages during the study. This led to fewer than 60% of patients reaching the full dosage of 2.4 mg for both Cagrilintide and Semaglutide, as outlined in the protocol. The average weight loss achieved was only 22.7%, significantly below the 25% target previously promoted.

These disclosures contradicted Novo’s earlier statements, raising questions about the company’s transparency and trial management. The announcement led to significant losses for investors, as $NVO plummeted nearly 18%.

Based on these events, $NVO investors filed a lawsuit against Novo Nordisk, claiming the company:

• It misled investors about the REDEFINE-1 trial’s methodology and expected results.

• It downplayed risks associated with the trial’s flexible dosing protocol and its impact on outcomes.

Investors believe Novo misrepresented the potential success of CagriSema.